Zantac Investor Class Action Time-Barred, Pa. Judge Rules

By Jonathan Capriel · March 4, 2026, 7:34 PM EST

The maker of heartburn and acid reflux relief tablet Zantac has defeated a securities fraud class action claiming the company hid for decades the cancer risks associated with the drug, causing...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

ROOFERS LOCAL NO. 149 PENSION FUND v. GSK PLC et al

Case Number

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Securities/Commodities

Date Filed

February 04, 2025

Recent Articles By Jonathan

March 02, 2026
Texas AG Says Gender Care Ban Includes Mental Health
February 25, 2026
NJ Judge Trims J&J And Neutrogena Benzene Suit
February 19, 2026
Judge Denies Mylan And Aurobindo's Bid To Escape Trial
February 18, 2026
Blue Shield Of Calif. Says 'Ghost Network' Action Falls Flat
February 13, 2026
FDA Removes Boxed Warnings From HRT Products
February 11, 2026
Zipper Malfunction In Hyperbaric Chamber Leads to Lawsuit
February 10, 2026
US Says Abbott Lied, Must Repay Funds Spent On Formula
December 03, 2025
FDA Seizes $1M In Illegal 7-OH Opioid Products
November 14, 2025
Texas Judge Rejects Bid To Block Kenvue's $398M Dividend
November 13, 2025
CVS Reaches Deal In 'Non-Drowsy' Labeling Class Action